Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.

"Disclosure Guilbert TW has received personal fees and/or grants from AiCME, Amgen, AstraZeneca, Best Pharmaceuticals for Children Act (BPCA), Genentech, GSK, NIH, Novartis, OM Pharma, Polarean, Polaris, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from UpToDate. Tolcachier A has conducted clinical trials for AstraZeneca, GSK, Novartis, and Sanofi, and received fees as a speaker for Novartis, Merck, and Sanofi. Fiocchi AG has acted as an advisor for Abbott, Danone, DBV Technologies, HiPP Organic, Novartis, and Stallergenes Greer, and received research sponsorship from Danone, Ferrero, HiPP Organic, and Sanofi. Katelaris CH was Principal Investigator of the dupilumab asthma phase 2b (NCT01854047) and phase 3 (NCT02414854) studies for Regeneron Pharmaceuticals Inc. and Sanofi. Phipatanakul W has acted as a consultant for and received clinical trial support/medication support from AstraZeneca, Genentech, GSK for Asthma Therapeutics, Merck, Regeneron Pharmaceuticals Inc., and Sanofi. Begin P has acted as Principal Investigator for DBV Technologies, Novartis, Regeneron Pharmaceuticals Inc., and Sanofi, and has received speaker/consulting fees from ALK, AstraZeneca, Aralez Bio, Bausch Health, DBV Technologies, Novartis, Pfizer, Sanofi, and Valeo Pharma. de Mir I has received fees for lectures, boards, and conferences from Aldo-Unión, GSK, and Novartis. Altincatal A is a Sanofi employee and may hold stock and/or stock options in the company. Gall R is a Regeneron Pharmaceuticals Inc. employee and shareholder. Ledanois O is a Sanofi employee and may hold stock and/or stock options in the company. Radwan A is a Regeneron Pharmaceuticals Inc. employee and shareholder. Jacob-Nara JA is a Sanofi employee and may hold stock and/or stock options in the company. Deniz Y is a Regeneron Pharmaceuticals Inc. employee and shareholder. Rowe PJ is a Sanofi employee and may hold stock and/or stock options in the company. The authors report no other conflicts of interest in this work."

"Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT02948959. Medical writing/editorial assistance was provided by Natalia Crespo, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines: 2022 update."